Sigyn Therapeutics Inc. (OTCMKTS:SIGY) was up 46% and 70% in a week. The company has completed a study that showed Sigyn Therapy’s ability to remove hepatic toxins from blood plasma.
On Friday, SIGY stock went up 46% at $0.95 with more than 10k shares, compared to its average volume of 967 shares. The stock has moved within a range of $0.6300 – 0.9750 after opening the trade at $0.63.
Rapid Elimination of Hepatic Toxins from Human Blood Plasma
Studies showed that Sigyn Therapy reduced bilirubin, toxins, bile acid, and ammonia, which are associated with Hepatic Encephalopathy (HE). This neurological condition appears in people with chronic liver disease and sudden liver failure. Sigyn Therapy is a patented blood purifying device that removes toxins, pathogens, and inflammatory targets from patients’ bloodstreams. The device was created to overcome the limitations of past blood-purifying devices.
Toxins accumulate in the bloodstream and eventually breach the blood-brain barrier, causing hepatic encephalopathy (HE). Severe HE cases can lead to significant, life-threatening consequences, such as loss of consciousness or coma. For example, in cirrhotic individuals with grade 3 and 4 cirrhosis, 30-day death rates of 38% have been documented. HE is a type of encephalopathy caused by liver disease. So in the coming weeks, SIGY is worth watching.
“We created Sigyn Therapy to overcome the limitations of previous blood purification technologies,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics. “The broad-spectrum clearance of hepatic toxins reinforces our therapeutic vision and expands the potential use of Sigyn Therapy to include acute and chronic liver indications.”